Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Effectiveness of Point-of-Care Diagnostics for Schistosomiasis, Reviewed

By LabMedica International staff writers
Posted on 16 Mar 2015
Findings from an independent review of studies suggests that currently available point-of-care (POC) tests are significantly less reliable than conventional microscopy, emphasizing the need for development of better and affordable POC diagnostics for schistosomiasis (bilharzia), classified as a neglected tropical diseases (NTD).

Simpler, more rapid POC tests with sufficient accuracy could replace microscopy for diagnosing schistosomiasis. More...
The review was conducted by researchers from the Cochrane Infectious Diseases Group hosted at the Liverpool School of Tropical Medicine (LSTM; Liverpool, UK) to estimate accuracy of the circulating antigen (CA) test for urinary schistosomiasis and intestinal schistosomiasis, and of urine reagent (URStrip) tests for urinary schistosomiasis.

Two independent authors identified and assessed 90 studies involving almost 200,000 people, with 88 of the studies from field settings in Africa. Studies compared POC tests to microscopy as reference standard: for Schistosoma haematobium—microscopy of urine prepared by filtration, centrifugation, or sedimentation; for S. mansoni—microscopy of stool by Kato-Katz thick smear.

Among the URStrip tests for urinary schistosomiasis, those for detecting blood (microhaematuria) were more accurate than those for detecting protein (proteinuria) or white cells (leukocyturia). Sensitivity and specificity estimates: for blood 75% and 87%; for protein 61% and 82%; for white cells 58% and 61%, respectively.

For urinary schistosomiasis, CA test performance was worse (39% sensitivity, 78% specificity) than URStrips for blood. For intestinal schistosomiasis, CA test detected many infections identified by microscopy but wrongly labeled many uninfected people as infected (89% sensitivity, 55% specificity).

“The simple test using a strip for testing blood in the urine worked well. The antigen tests for the disease did not work so well for urinary schistosomiasis, and in intestinal schistosomiasis it may classify many uninfected people as infected and lead to unnecessary treatment,” said lead author Dr. Eleanor Ochodo, Stellenbosch University.

LSTM’s Prof. Russell Stothard, international expert in schistosomiasis and director of the new COUNTDOWN research consortium, which will trial and evaluate new approaches to drug distribution in NTD program, said: “Those in the field of NTD research and control welcome reviews of this kind, looking at the efficacy of diagnostic tests for diseases affecting some of the poorest communities in the world. They draw together largely fragmented literature into one place, allowing quick appraisal for informed decision-making. Reviews such as this will ensure that COUNTDOWN benefits from the best research intelligence from within the NTD community and stays well informed throughout.”

The review, by Ochodo EA et al., was published online March 11, 2015, in Cochrane Database of Systematic Reviews.

Related Links:

Cochrane Infectious Diseases Group
Liverpool School of Tropical Medicine (LSTM)



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.